Background: Phase I trials are designed to determine the safety, tolerability, and recommended phase 2 dose of therapeutic agents for subsequent testing. The dose-finding paradigm has thus traditionally focused on identifying the maximum tolerable dose of an agent or combination therapy under the assumption that there is a non-decreasing relationship between dose-toxicity and dose-efficacy. The dose is typically determined based on the probability of severe toxicity observed during the first treatment cycle. A novel endpoint, the total toxicity profile, was previously developed to account for the multiple toxicity types and grades experienced in the first cycle. More recently, this was extended to a repeated measures design based on the total toxicity profile to account for longitudinal toxicities over multiple treatment cycles in the absence of within-patient correlation. Methods: In this work, we propose to extend the design in the presence of within-patient correlation. Furthermore, we provide a framework to detect a toxicity time trend (toxicity increasing, decreasing, or stable) over multiple treatment cycles. We utilize a linear mixed model in the Bayesian framework, with the addition of Bayesian risk functions for decision-making in dose assignment. Results: The performance of this design was evaluated using simulation studies and real data from a phase I trial. We demonstrated that using available toxicity data from all cycles of treatment improves the accuracy of maximum tolerated dose identification and allows for the detection of a time trend. The performance is consistent regardless of the strength of the within-patient correlation. In addition, the use of a quasi-continuous total toxicity profile score significantly increased the power to detect time trends compared to when binary data only were used. Conclusion: The increased interest in molecularly targeted agents and immunotherapies in oncology necessitates innovative phase I study designs. Our proposed framework provides a tool to tackle some of the challenges presented by these novel agents, specifically through the ability to understand patterns of toxicity over time, which is important in the cases of cumulative or late toxicities.
Introduction
Phase I trials are designed to determine the safety, tolerability, and recommended phase 2 dose of therapeutic agents for subsequent testing. The dose-finding paradigm has traditionally focused on identifying the maximum tolerable dose (MTD) of an agent or combination of agents based on toxicity with the assumption that there is a positive, proportional relationship between dose and tumor cell kill (efficacy). In conventional dose-finding designs, only the dose-limiting toxicities (DLT) within the first cycle of treatment have been considered in the decision-making; adverse events occurring in later treatment cycles are not formally considered. Furthermore, a binary variable indicating the occurrence of DLT based on grade 3-4 events is generally utilized, discarding mild or moderate toxicities or the risk that a patient suffers from multiple adverse events during the same treatment cycle.
Over the past decade, the emergence of molecularly targeted agents and immune checkpoint-targeted antibodies has necessitated changes to the early drug development process. 1 These agents have milder toxicity profiles and thus the definition of DLT only taking account of grade 3-4 toxicities may not be appropriate. Among 13 phase 1 trials of immunotherapies, 2-12 low rates of grade 3-4 toxicities were observed ( \14%) in 12 trials, except for 1 trial 10 where 36% grade 3-4 toxicities (10/28 patients) were observed, although 4 DLTs were late-onset in that trial. Hence, most trials were not able to identify a MTD which was defined per-protocol to target a 17%-33% DLT occurrence. Recent studies found that more than half of the 445 patients in the 36 clinical trials of molecular targeted agents developed their worse grade toxicity after the first cycle, 13 for example, immune-related adverse events from ipilimumab were reported to occur 8-10 weeks after the treatment initiation. 10 Therefore, it is clear that for these agents, both lower grade toxicity and toxicities observed beyond cycle 1 should be considered during the dose-finding process.
A variety of toxicity scoring systems have been proposed to measure quantitatively and comprehensively the overall severity of multiple toxicities for a patient, such as the equivalent toxicity score 14 or total toxicity burden. 15 Suppose that there are k = 1, . . . , K patients, let T ik be the ith (i = 1, . . . , K I ) toxicity event of the kth patients. Equivalent toxicity score converts each toxicity event T ik into a numerical value of adjusted grade G ik pre-defined according to the severity of the toxicity event, while total toxicity burden is defined as the sum of the weights of all toxicities experienced by a patient, where weight reflects the relative clinical importance of each grade and type of toxicity.
Few dose-finding designs have been proposed that take into account toxicities from subsequent treatment cycles. Cheung and Chappell 16 proposed a sequential dose-finding design using time to first DLT occurrence as the endpoint where interest is in measuring the risk of cumulative toxicities over a given period. 16 A dosefinding design using a mixed-effect proportional odds model for longitudinal ordinal toxicity in phase I oncology trials was proposed by Doussau et al., 17 which was suboptimal in the case of scarce data. We previously developed a Bayesian phase I design, 18 incorporating a quasi-continuous toxicity endpoint, the total toxicity profile (TTP), from multiple treatment cycles. The TTP score captures a comprehensive toxicity profile including multiple types and grades of toxicities occurring during the first treatment cycle. 19 The repeated measures design using longitudinal toxicity data from multiple cycles (assuming independence across cycles) improved the ability to identify the MTD compared to a design that utilized data from just one cycle. 18 In this work, we further investigate the performance of the repeated measures design to detect toxicity trends over time both in the presence and absence of correlated toxicity data within a patient who receives multiple treatment cycles over time. The information about the time trend of the toxicity profile is important to guide the drug administration over time, especially in the setting of molecular targeted agents which are usually administered until disease progression or unacceptable toxicity.
In our previous work, we have focused exclusively on dose-finding methodology only. And in this article, the focuses are now toward time-trend detection methods and implementation. Different from our previous work, posterior estimates in toxicity from all cycles were used to make inference on time trend. In practice, it could help identify potential cumulative mild/moderate toxicities and late on-set toxicities associated with molecular targeted agents and immunotherapies, when a significant positive trend is present. A method to generate correlated multinomial data was utilized in this article. Phase I data in reality are multi-dimensional, and therefore, the process of generating complex but realistic phase I toxicity data is a challenge. Previously, we generated data in a simpler manner: independent longitudinal toxicity data using a non-parametric approach. In this article, we generated correlated longitudinal toxicity data and demonstrated that the strength of within-patient correlation has minimal impact on the performance of the model-based design. Furthermore, a different comparator is used in this article: the quasi-likelihood continual reassessment method design was used in our previous work to assess dose-finding performance, whereas the LMM-CRML (logistics mixed effect model -continual reassessment method with likelihood reference) was used here to compare the time-trend detection capabilities of a continuous toxicity score to a DLT binary endpoint. In addition to the simulation tools we applied in the previous work, we further introduced a real-life example using the individual patient data from a National Cancer Institute sponsored phase I trial in this article. This is the first demonstration of TTP-based toxicity over time in a real phase I trial.
The article is organized as follows: we first review the extension to the repeated measures design using the longitudinal TTP scores from multiple treatment cycles for dose escalation. We then introduce an approach for generating correlated longitudinal toxicity data. Simulation results are presented for the performance of the repeated measures design in the presence of withinpatient correlation (to account for the repeated toxicities from multiple cycles within a given patient). The main findings of this work and ideas for future research are presented in the ''Discussion'' section.
Motivating example
A recent phase I study (NCT00048334) explored a day 1, 3, and 5 schedule of romidepsin, a potent histone deacetylase inhibitor, in patients with advanced solid tumors, 20 using a 3 + 3 dose-escalation design. DLT was defined in the first cycle (21 days) as a hematologic toxicity of grade 4 absolute granulocyte count for more than 5 days; grade 4 platelet count; grade 3 + nonhematologic toxicity, excluding potassium, magnesium, calcium, phosphate, uric acid, nausea, and vomiting unless these events are scored as grade 4 or occur despite maximal prophylaxis. Twenty-eight patients were evaluated at six increasing doses of romidepsin ranging from 1 to 9 mg/m 2 . Two patients experienced a DLT: one patient had a grade 3 hypoxia and atrial fibrillation at dose level 2 (2 mg/m 2 ) and the other patient had difficult-to-treat grade 3 nausea and anorexia at dose level 6 (9 mg/m 2 ). While no other patient had a DLT at dose 9 mg/m 2 (DLT probability = 11%, 95% confidence interval (CI): 0.3-48), most patients did not tolerate prolonged dosing at 9 mg/m 2 . Late toxicities were observed and prompted dose reduction in 7 out of the 9 patients enrolled at 9 mg/m 2 . The 7 mg/m 2 dose was therefore the recommended phase II dose with the option to increase to 9 mg/m 2 if tolerable by the patient. A total of 100 cycles were delivered to 28 patients; 11 patients received six cycles of treatment. In total, 114 cases of grade 3 toxicity and 5 cases of grade 4 toxicity (in 4 patients) were recorded, including 93 grade 3 and 4 toxicities after the first cycle.
Methods

Repeated measures design model and estimation
Yin et al. 18 previously developed a Bayesian phase I design accounting for comprehensive toxicity profiles from multiple treatment cycles for dose-finding. Patient-level toxicity profiles were quantified by a quasi-continuous toxicity score, the TTP, first proposed by Ezzalfani et al. 19 To compute the TTP score, the specific toxicities have to be identified and their possible outcomes graded by the Common Terminology Criteria for Adverse Events, 21 which ranges from grade 0 (no toxicity) to grade 4 (life-threatening). Note that we limit the toxicity outcome to only grade 0-4, because the occurrence of a grade 5 event, corresponding to death, would require direct interaction between the entire study team and potentially regulatory bodies to determine whether to continue or terminate the trial. Prespecified weights are then assigned to the toxicities to characterize the clinical importance of each grade of each type of toxicity. Given a patient's observed toxicity profile, the TTP score is computed as the Euclidean norm of the weight matrix given the observed toxicity.
To be consistent with Ezzalfani et al., 19 let us consider three types of toxicities: renal, neurologic, and hematologic toxicities. Table 1 lists the possible toxicity outcomes, severity weight for each outcome, and whether its occurrence is considered a DLT. A patient with grade 2 renal, grade 0 neurologic, and grade 4 hematologic toxicities will have TTP = ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi 0:75 2 + 0 + 1 2 p = 1:25. The TTP is further divided by a normalization constant v, so that the resulting nTTP score is within the range of (0, 1): nTTP = TTP/v (more details on normalization are available in article by Ezzalfani et al. 19 ).
Yin et al. 18 proposed an adaptive dose-finding design based on the nTTP using a repeated measures model for longitudinal toxicity data. Due to the small sample size in phase I trials, parsimonious parametric models have been preferred as a working model to guide dose escalation; [22] [23] [24] therefore, a linear model with a random intercept to model the longitudinal toxicity data was used. Assume that n patients are to be sequentially enrolled with K dose levels: x 1 , . . . , x k representing the dose at K levels, and further assume that a patient i is treated at the same dose throughout the trial at all the cycles j = 1, . . . , J . Let y ij denote the observed nTTP value for the patient i at the cycle j. The linear mixed model can be described as
where b 0 is the effect of the intercept; b 1 captures the dose-toxicity relationship (we assume a monotonically increasing relationship where b 1 .0); b 2 captures the time trend of toxicity where b 2 .0 implies an increasing toxicity over time and b 2 \0 implies a decreasing toxicity rate over time; e ij is the measurement error e ij ;N(0, s 2 ); and g i is the random intercept for each patient where g i ;N (0, s 2 g ) and s 2 g is the variance of the random intercept. Assuming that each patient has a different overall tolerance to treatment, the random intercept g i is introduced to account for the correlation within the same patient for toxicities observed over repeated cycles of treatments, as well as contributing to the inter-patient variability. The MTD is defined as the dose with the nTTP score at cycle 1 closest to the pre-specified target p 1 in the Bayesian risk function: argmin x k EjnTTP 1 (x k ) À p 1 j, where nTTP 1 (x k ) represents the nTTP score at cycle 1 given dose x k . The Bayesian risk is defined as the posterior expected value of the distance between nTTP 1 (x k ) and p 1 . Although the decision rule is only based on the target toxicity at cycle 1, the accumulated toxicity data from multiple treatment cycles is utilized in the parameter estimation. A Bayesian inference paradigm coupled with a Markov chain Monte Carlo algorithm is adopted here similar to the original continual reassessment method design. 25 We have also run additional simulations that defining MTD using multiple cycles of data upon completion of the trial. More details are included in the online appendix.
Repeated measures design dose-escalation procedure
Following the principle of adaptive dose-finding designs, patients are sequentially enrolled starting with the lowest dose. Estimates of the toxicity score at dose level k at cycle 1, nTTP 1 (x k ), are obtained using Model (1); the decision criteria for dose allocation is based on the selection of the dose that minimizes EjnTTP 1 (x k ) À p 1 j. A new cohort of patients is enrolled at the selected dose only after the previous cohort completes at least one cycle of treatment. The algorithm can be summarized as below:
1. The 3 + 3 design is used for the first two patient cohorts as a run-in, to provide data for initial parameter estimation before switching to Model (1). 2. After run-in, before each new cohort of patients are treated: (a) Fit the linear mixed model using all collected data from all patients treated thus far in the trial. (b) Evaluate the decision criteria and identify the recommended dose that minimizes the Bayesian risk between the estimated nTTP score and the target nTTP score at cycle 1. (c) Treat the new cohort with the recommended dose, or the next higher dose if a decision is made that dose levels may not be skipped during dose escalation. (d) No intra patient dose escalation is permitted:
patients are treated with the same dose until they are removed from the trial due to excessive toxicity or disease progression. 3. Terminate the trial when the pre-specified maximum number of patients has been reached.
Upon completion of the trial, the trend in the toxicity over time (from multiple cycles of treatment) can be estimated using the complete longitudinal data. The 95% credible interval of b 2 from Model (1) is computed: if the 95% credible interval does not include 0, it indicates the presence of a time effect (increasing or decreasing); otherwise, we conclude that the evidence does not support the presence of a time effect.
Simulation studies
Simulation studies were used to assess the performance of the repeated measures design in terms of recommending the correct dose and time-trend detection. We included a fixed sample size of 36 patients and considered six dose levels. Every patient was administered a maximum of six treatment cycles, and treatment was stopped anytime if the patient experienced a DLT, generating missing data at subsequent cycles.
Data generation
We extended the approach of Ezzalfani et al. 19 of generating nTTP data for the first cycle to generate correlated toxicity data over multiple cycles. In Ezzalfani et al., three toxicity types (renal, neurological, and hematological) were considered for illustration purposes and they were assumed independent; the associated weight matrix and the indicator of DLT are shown in Table 1 . For each toxicity type, the probability matrix of observing grade 0-4 at each dose level (from dose level 1 to 6) was pre-defined (details can be found in the study by Ezzalfani et al. 19 ). We used the pre-defined toxicity probabilities in the article by Ezzalfani et al. 19 as the marginal toxicity probabilities for cycle 1, and then extended these toxicity probabilities for subsequent cycles assuming an increasing, flat, and decreasing time trend, as detailed below.
Denote the marginal toxicity probability at cycle j ( j = 1,.,J) as p j, lh (x) of observing a grade h (h = 0,1,2,3,4) for toxicity type l (l = 1,2,3) at dose x k . The marginal toxicity probabilities capture the mean structure of the ordinal toxicity data, including the marginal dose-toxicity relationship and the marginal dose-cycle relationship (Figure 1 ). The ordinal toxicity data generated from the marginal toxicities are considered independent across and within the cycles (see supplemental online appendix for details). To induce correlation among the repeated measures over cycles within a patient, we employed a latent random effect. Specifically, if we denote the individual toxicity probability at cycle j as p ij, lh (x) for patient i, and, w ih as the random effect that captures the within-patient correlation across multiple cycles, a Baseline-Categorical Logit model incorporating this can be denoted as below 26 log
In this model, w ih is the random intercept, following a Gaussian distribution w ih ;N (0, s 2 w ) with an exchangeable correlation structure, and the parameter s 2 w controls the degree of correlation between cycles. The sum of the probability of observing a toxicity grade from 0 to 4 equals to 1 for any toxicity type: P 4 h = 0 p ij, lh (x k ) = 0, for any i, j, l and k.
Simulation scenarios
We considered 12 clinical scenarios in total, with 4 different MTD locations (dose 2, dose 3, dose 4, and dose 5) and 3 different time trends (no time trend, decreasing time trend, and increasing time trend). A total of 500 trials were simulated for each scenario. The MTD is defined as the dose level where the nTTP equals the target of 0.28 at cycle 1, which corresponds to a probability of DLT of 33% (please refer to the study by Ezzalfani et al. 19 for details on the target nTTP). The scenarios where the true MTD is, respectively, dose level 2, 3 or 4, and 5 represent severe, moderate, and mild dose-toxicity relationships. In addition, we also conducted simulations with patient dropout due to disease progression. More details are included in the online appendix demonstrating the consistent performance of our model in these scenarios. Additional results for true MTD dose = 1 are also available in the appendix.
Performance evaluation criteria
For the dose-finding evaluation, we evaluated the percentage of correct selection which is the proportion of the trials recommending the true target dose. We also reported the percentage of patients assigned to each dose level to evaluate the safety and efficiency of repeated measures design. The quasi-likelihood continual reassessment method 19 is used as a benchmark for comparison. The quasi-likelihood continual reassessment method is an extension of the continual reassessment method approach where nTTP scores instead of DLTs from cycle 1 are used as the toxicity outcome. In the quasi-likelihood continual reassessment method, nTTP scores were assumed to follow quasi-Bernoulli distributions and were modeled using logistic regression models. As in conventional phase I trials, the quasilikelihood continual reassessment method only uses toxicity from cycle 1 for dose escalation, and hence is not applicable for time-trend detection. For time-trend detection, we reported the percentage of simulations where a time trend was detected at the 5% level. Tests were carried out at the end of each trial by comparing the 95% credible interval of b 2 , which is the estimate of time effect, to 0. A significant time trend was declared when the 95% credible interval of b 2 excluded 0.
Results
Dose-finding
Within-patient correlated toxicity data over cycles were generated by the above Baseline-Categorical Logit model (equation (2)); the parameter value of s 2 w was set to 10. Additional simulation scenarios of correlation parameters are available in the online appendix. Distributions of dose assignment and final dose recommendation are displayed in Table 2 . Since the quasilikelihood continual reassessment method only uses cycle 1 data, we first fit the repeated measures design model to cycle 1 data only (denoted as ''RMD, cycle 1'' in Table 2 ) for a fair comparison. Repeated measures design and quasi-likelihood continual reassessment method are comparable when only cycle 1 toxicity data were used. We then applied repeated measures design to longitudinal toxicity data from multiple cycles. In the absence of any time effect (denoted as ''RMD, constant trend'' in Table 2 ), the repeated measures design model of longitudinal toxicity data improved the identification of the target dose compared to the quasilikelihood continual reassessment method and the repeated measures design using just cycle 1 data (4%-9% improvement in percentage of correct selection) in all scenarios except when MTD was dose 2; the mean number of cycles was 2.0-3.1 per patient. Therefore, using toxicity data from multiple cycles is advantageous in the presence of no detectable time trend.
In case of an underlying true negative time effect (denoted as ''RMD, decreasing trend'' in Table 2 ), the repeated measures design model of longitudinal toxicity data consistently improved the identification of the target dose in all scenarios (an improvement of 3%-6% in percentage of correct selection, compared to quasilikelihood continual reassessment method); the mean number of cycles was 2.6-3.4 per patient. In case of an underlying true positive time effect (denoted as ''RMD, increasing trend'' in Table 2 ), repeated measures design performed slightly worse in severe dose-toxicity scenarios when the true MTD was dose levels 2 or 3 (4% less in percentage of correct selection than the Table 2 . Dose recommendation and allocation percentage, with within-patient correlated toxicity data over cycles.
Dose recommendation Dose allocation
No. of cycles (mean, SD)
True quasi-likelihood continual reassessment method), but better in mild dose-toxicity scenarios when the true MTD was dose levels 4 or 5 (5%-7% gain in percentage of correct selection, compared to the quasilikelihood continual reassessment method); the mean number of cycles was 1.6-2.7 per patient. Table 3 reports the percentage of trials where a time trend was detected at the completion of the trial using the longitudinal analysis at the 5% level. The false positive rate in the absence of a time trend is less than 13% in all scenarios, indicating an acceptable type I error control. In scenarios when a positive trend was present, the test for trend was significant in 56%-67% of the trials, indicating promising power for detecting a positive trend. In scenarios when a negative trend was present, a considerable loss of power was observed (9%-19% power) with repeated measures design. The loss of power was mainly due to the missing data from DLT dropout. Within the treatment paradigm for each patient, treatment was stopped anytime a DLT was observed, leading to patient dropouts in later cycles for toxic scenarios (see Figure S1 in the appendix for more details). Hence, in the presence of a negative trend, the data to demonstrate the lower toxicity in subsequent cycles were frequently absent. To have a better idea of the bias, although unrealistic, we also considered an analysis with complete longitudinal data, where all patients completed their six cycles of treatment, regardless of DLT occurrence. As expected, the power was above 98% for all the scenarios in this instance.
Time-trend detection
We further investigated the performance of repeated measures design when a stronger time effect was present in the data: the slope of time effect was increased by 95%-126% for positive trends and 72%-110% for negative trends (please see the online appendix for details). In the simulated data with a stronger time trend, the power of detecting a positive trend increased to above 88% and the power of detecting a negative trend increased to 56%-74% (Table 3 ).
Application
The data from the romidepsin trial previously introduced were reanalyzed using the continuous nTTP scores. Only the final estimates of the time effect using the complete data are provided here, as the retrospective analysis of dose allocation is not directly feasible. For illustration purpose, we considered the three frequent types of toxicities: gastrointestinal (23.4%), liver (9.7%), and hematological (32.3%) adverse events, and their severity weights were assigned as in the following weight matrix (column represents grade 0-4, and row represents toxicity type in the order of gastrointestinal, liver, and hematological toxicity) If a patient had multiple toxicities for a given type during the same cycle, only the maximum grade for that toxicity type was considered. The number of patients remaining in the study decreased over time (approximately half of the patients dropped out after cycle 2), grade 2 toxicities were experienced in later cycles, and grade 3/4 hematological toxicities occurred in cycles 5 and 6 ( Table 4 ). Figure 2 shows the observed average nTTP per cycle (dashed line) and the predicted nTTP (solid line) from the repeated measures design model, demonstrating a good fit to the data despite the few patients per cycle. Analysis with repeated measures design yielded an estimate of time effect of 0.03 (95% CI: 0.01-0.04), which equals to a 12% increase in the toxicity score (12% = 0.03/0.25) from cycle 1 to cycle 2, if the observed nTTP = 0.25 in cycle 1. A caveat to this analysis is that only the planned dose was available instead of the actual administrated dose, especially for Within-patient correlated toxicity data over cycles were generated by the Baseline-Categorical Logit model (equation (2)) with the parameter value of s 2 w set equal to 10. b The slope of time effect was increased by 95%-126% for positive trend, and 72%-110% for negative trend. Please see the online appendix for details on how to generate ordinal toxicity data with a stronger time effect.
the seven patients who had a dose reduction from 9 to 7 mg/m 2 in the subsequent cycles due to toxicities.
Discussion
Recent development of cancer immunotherapies and molecularly targeted agents require innovative approaches beyond the traditional phase I designs commonly used for cytotoxic agents. Specifically, immunotherapies and molecular targeted agents often demonstrate reduced rates of severe toxic reactions; however, their adverse effects may persist or even accumulate over multiple treatment cycles, as opposed to the acute toxicities experienced with cytotoxic agents often observed in the first treatment cycle. Since prolonged minor to moderate toxicities can have a significant impact on a patient's quality life, 27 treatment compliance [28] [29] [30] or even be life-threatening if not properly managed, [31] [32] [33] it is important to assess the trend of toxicity events across multiple treatment cycles.
In this study, we demonstrated through simulation studies that using available toxicity data from all cycles of treatment improves the accuracy of MTD identification and allows the detection of a time trend in many instances. In the absence of within-patient correlation, the repeated measures design consistently improved the estimation of the MTD; when within-patient correlation was present, the repeated measures design performed better than the quasi-likelihood continual reassessment method 34 in most cases. In the presence of a strong within-patient correlation, similar results were observed between the repeated measures design and the quasi-likelihood continual reassessment method (Table  S1 ). In addition, the use of a quasi-continuous toxicity score (TTP) significantly increased the power to detect time trends compared to when binary DLT data were used.
The repeated measures design methods require input from the physicians involved in the trial. We note that this is no different than any other phase I trial where the study team has to identify unacceptable grades and types of toxicities a priori. Initially, the physicians need to specify toxicities to be monitored and their possible clinical outcomes graded by the Common Terminology Criteria for Adverse Events. As an example, we use three types of toxicities: renal, neurological, and hematological toxicities, for illustration purposes. The physicians are then asked to assign a severity weight for each grade of each toxicity within some numerical range. As the method is invariant to the range, the range only needs to be positive. Grade 0 corresponds to no toxicity and a null weight. We demonstrated one way of specifying the severity weights in the example. Based on the severity weights, the most severe toxicity profile (grade 4 for all three toxicity types) corresponds to a maximum TTP score of 2.34. In this case, the normalization constant was chosen as 2.5, just so it is slightly larger than the maximum TTP. By dividing TTP scores by the normalization constant, the nTTP scores are constrained between 0 and 1. The assumption of normality of the toxicity score, nTTP (either the raw as used in the simulations or transformed scores, in case of skewed data), is necessary for the linear mixed-effect model assumptions. A natural extension would be to explore non-linear models with other link functions.
An interesting finding of this study is the lack of power to detect negative trends due to missing data from patient dropout in the later cycles. In the presence of a negative trend in toxicity over time (i.e. decreasing relationship between toxicity and cycle within each dose level), when a patient stops treatment due to a severe toxicity, the ability to observe the decreasing toxicity trend at subsequent cycles is compromised. The loss of power was even more remarkable when only a dichotomized toxicity endpoint (i.e. DLT) was used 35 (details in online appendix). In practice, the existence of a decreasing trend may be considered less critical, as a dose that causes excessive early toxicity generally would not be considered appropriate even if the rate of toxicity could be lower in subsequent cycles. A study of 54 phase I cancer clinical trials of molecular targeted agents from 1999 to 2013 found that approximately 20% of the patients had to be dose reduced after cycle 1. 36 Recently, ceritinib was approved by the Food and Drug Administration at the MTD determined based on toxicity from cycle 1; however, it was associated with late toxicity resulting in dose reduction for half of the patients in the trial. 37 Sensitivity analyses were conducted to investigate the performance of repeated measures design under varying strength of within-patient correlation. The parameter s 2 w in the Baseline-Categorical Logit model (equation (2)) controls the degree of correlation in the longitudinal data: larger values of s 2 w result in stronger correlation in the data. A minimal reduction ( \6%) in the percentage of correct selection was observed in some scenarios when stronger within-patient correlation was present (see online appendix for details). No impact was observed in terms of time-trend detection.
To conclude, the novelty of this approach includes three key features: (1) we extended our previously published repeated measures design to allow for time-trend detection upon the completion of the trial. Our prior work focused only on dose-finding. We have demonstrated that the use of a continuous toxicity endpoint significantly increases the power to detect time trends compared to a binary endpoint; (2) we introduced a method to generate correlated multinomial data, and identified that the strength of within-patient correlation has minimal impact on the performance of this modelbased design; and (3) we utilized individual patient data from a National Cancer Institute sponsored phase I trial, and applied our methods to the trial. Our proposed design provides a potential tool to tackle challenges presented by molecular targeted agents and immunotherapies.
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